The relationship between stomach Helicobacter pylori infection and antibiotic consumption among HIV-positive individuals

Evolution of Helicobacter pylori primary antibiotic resistance in a cohort of individuals with and without HIV infection: role of antibiotics consumption

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN13466428

Enrollment

180

Registered

2020-10-03

Start date

2006-01-01

Completion date

Unknown

Last updated

2021-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori antimicrobial susceptibility in people with HIV infection Infections and Infestations H. pylori infection

Interventions

Participants who fulfil inclusion criteria will be asked to give consent for the team to collect clinical information, as well as data related to H. pylori diagnosis. We prospectively

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. No history of H. pylori treatment 2. Ambulatory HIV-positive and HIV-negative individuals 3. Naïve to H. pylori treatment 4. Aged =18 years 5. Underwent upper gastrointestinal endoscopy for any reason and for which H. pylori antimicrobial susceptibility test results is available

Exclusion criteria

Exclusion criteria: 1. Coagulopathy 2. Partial gastrectomy 3. Does not agree to participate

Design outcomes

Primary

Measure	Time frame
1. Primary H. pylori antibiotic resistance is evaluated by anamnesis and by microbial examination of gastric samples using disk diffusion methods (Neo-Sensitabs; Rosco, Taastrup, Denmark), and the minimum inhibitory concentration (MIC) determined by an agar dilution method at a single time point 2. Antibiotic consumption within the country during the period studied, measured by defined daily dose per 1000 inhabitants using national records	—

Measure

Time frame

1. Primary H. pylori antibiotic resistance is evaluated by anamnesis and by microbial examination of gastric samples using disk diffusion methods (Neo-Sensitabs; Rosco, Taastrup, Denmark), and the minimum inhibitory concentration (MIC) determined by an agar dilution method at a single time point 2. Antibiotic consumption within the country during the period studied, measured by defined daily dose per 1000 inhabitants using national records

—

Secondary

Measure	Time frame
Measured at the time of H. pylori diagnosis: 1. Demographics measured using anamnesis, medical records, and hospital database 2. History of H. pylori treatment obtained by anamnesis, patient’s medical chart, phone contact with the family medical doctor 3. HIV status measured using medical records 4. HIV viral load (measured using COBAS AmpliPrep/COBAS Amplicor HIV-1 Monitor Test v1.0, 1COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 real time PCR) 5. Lymphocyte T CD4 count (measured using flow cytometry, NAVIOS) 6. Chemoprevention against Toxoplasma gondii or Pneumocystis jiroveci ( with trimethoprim-sulfamethoxazole ) or anti-malaria drug use (including mefloquine, atovaquone, chloroquine, primaquine) 7. Consequences of infection measured by endoscopy performed using video Olympus GIF-q165, GIF-HQ 190 and gastric biopsy	—

Measure

Time frame

Measured at the time of H. pylori diagnosis: 1. Demographics measured using anamnesis, medical records, and hospital database 2. History of H. pylori treatment obtained by anamnesis, patient’s medical chart, phone contact with the family medical doctor 3. HIV status measured using medical records 4. HIV viral load (measured using COBAS AmpliPrep/COBAS Amplicor HIV-1 Monitor Test v1.0, 1COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 real time PCR) 5. Lymphocyte T CD4 count (measured using flow cytometry, NAVIOS) 6. Chemoprevention against Toxoplasma gondii or Pneumocystis jiroveci ( with trimethoprim-sulfamethoxazole ) or anti-malaria drug use (including mefloquine, atovaquone, chloroquine, primaquine) 7. Consequences of infection measured by endoscopy performed using video Olympus GIF-q165, GIF-HQ 190 and gastric biopsy

—

Countries

Belgium

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 15, 2026